{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:28:16Z","timestamp":1791419296111,"version":"4.3.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010664","name":"H2020 Future and Emerging Technologies","doi-asserted-by":"publisher","award":["732170"],"award-info":[{"award-number":["732170"]}],"id":[{"id":"10.13039\/100010664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Transcatheter tricuspid valve intervention became an option for pacemaker lead-associated tricuspid regurgitation. This study investigated the progression of tricuspid regurgitation (TR) in patients with or without pre-existing right ventricular dilatation (RVD) undergoing pacemaker implantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were included if they had implantation of transtricuspid pacemaker lead and completed echocardiography before and after implantation. The cohort was divided in patients with and without RVD (cut-off basal RV diameter\u2009\u2265\u200942\u00a0mm). TR was graded in none\/mild, moderate, and severe. Worsening of one grade was defined as progression. Survival analyses were plotted for 10\u00a0years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 990 patients were analyzed (24.5% with RVD). Progression of TR occurred in 46.1% of patients with RVD and in 25.6% of patients without RVD (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Predictors for TR progression were RV dilatation (OR 2.04; 95% CI 1.27\u20133.29;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.003), pre-existing TR (OR 4.30; 95% CI 2.51\u20137.38;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), female sex (OR 1.68; 95% CI 1.16\u20132.43;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.006), single RV lead (OR 1.67; 95% CI 1.09\u20132.56;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.018), mitral regurgitation (OR 2.08; 95% CI 1.42\u20133.05;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), and enlarged left atrium (OR 1.98; 95% CI 1.07\u20133.67;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.03). Survival-predictors were pacemaker lead-associated TR (HR 1.38; 95% CI 1.04\u20131.84;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.028), mitral regurgitation (HR 1.34; 95% CI 1.02\u20131.77;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.034), heart failure (HR 1.75; 95% CI 1.31\u20132.33;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), kidney disease (HR 1.62; 95% CI 1.25\u20132.11;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), and age\u2009\u2265\u200980\u00a0years (HR 2.84; 95% CI 2.17\u20133.71;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with RVD receiving pacemaker suffered from increased TR progression, leading to decreased survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphic abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-021-01812-3","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T14:54:06Z","timestamp":1612968846000},"page":"884-894","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Pacemaker lead-associated tricuspid regurgitation in patients with or without pre-existing right ventricular dilatation"],"prefix":"10.1007","volume":"110","author":[{"given":"Martin","family":"Riesenhuber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Spannbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Gwechenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pezawas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schukro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Stix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Goliasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahit","family":"Anvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wrba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Khazen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Andreas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Laufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hengstenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariann","family":"Gyongyosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"1812_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jcmg.2018.06.014","volume":"12","author":"Y Topilsky","year":"2019","unstructured":"Topilsky Y, Maltais S, Medina Inojosa J et al (2019) Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging 12:433\u2013442. https:\/\/doi.org\/10.1016\/j.jcmg.2018.06.014","journal-title":"JACC Cardiovasc Imaging"},{"key":"1812_CR2","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1016\/S0140-6736(16)00740-6","volume":"388","author":"J Rod\u00e9s-Cabau","year":"2016","unstructured":"Rod\u00e9s-Cabau J, Taramasso M, O\u2019Gara PT (2016) Diagnosis and treatment of tricuspid valve disease: current and future perspectives. Lancet 388:2431\u20132442. https:\/\/doi.org\/10.1016\/S0140-6736(16)00740-6","journal-title":"Lancet"},{"key":"1812_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jacc.2003.09.036","volume":"43","author":"J Nath","year":"2004","unstructured":"Nath J, Foster E, Heidenreich PA (2004) Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol 43:405\u2013409. https:\/\/doi.org\/10.1016\/j.jacc.2003.09.036","journal-title":"J Am Coll Cardiol"},{"key":"1812_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jacc.2017.03.011","volume":"70","author":"RA Nishimura","year":"2017","unstructured":"Nishimura RA, Otto CM, Bonow RO et al (2017) 2017 AHA\/ACC focused update of the 2014 AHA\/ACC guideline for the management of patients with valvular heart disease. J Am Coll Cardiol 70:252\u2013289. https:\/\/doi.org\/10.1016\/j.jacc.2017.03.011","journal-title":"J Am Coll Cardiol"},{"key":"1812_CR5","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","volume":"38","author":"H Baumgartner","year":"2017","unstructured":"Baumgartner H, Falk V, Bax JJ et al (2017) 2017 ESC\/EACTS guidelines for the management of valvular heart disease. Eur Heart J 38:2739\u20132791. https:\/\/doi.org\/10.1093\/eurheartj\/ehx391","journal-title":"Eur Heart J"},{"key":"1812_CR6","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2018.04.031","volume":"71","author":"L Asmarats","year":"2018","unstructured":"Asmarats L, Puri R, Latib A et al (2018) Transcatheter tricuspid valve interventions. J Am Coll Cardiol 71:2935\u20132956. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.031","journal-title":"J Am Coll Cardiol"},{"key":"1812_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv766","author":"M Taramasso","year":"2016","unstructured":"Taramasso M, Pozzoli A, Guidotti A et al (2016) Percutaneous tricuspid valve therapies: the new frontier. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehv766","journal-title":"Eur Heart J"},{"key":"1812_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcin.2018.10.022","volume":"12","author":"M Taramasso","year":"2019","unstructured":"Taramasso M, Alessandrini H, Latib A et al (2019) Outcomes after current transcatheter tricuspid valve intervention. JACC Cardiovasc Interv 12:155\u2013165. https:\/\/doi.org\/10.1016\/j.jcin.2018.10.022","journal-title":"JACC Cardiovasc Interv"},{"key":"1812_CR9","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.jacc.2019.01.062","volume":"73","author":"G Nickenig","year":"2019","unstructured":"Nickenig G, Weber M, Schueler R et al (2019) 6-Month outcomes of tricuspid valve reconstruction for patients with severe tricuspid regurgitation. J Am Coll Cardiol 73:1905\u20131915. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.062","journal-title":"J Am Coll Cardiol"},{"key":"1812_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jchf.2019.12.006","volume":"8","author":"M Orban","year":"2020","unstructured":"Orban M, Rommel K-P, Ho EC et al (2020) Transcatheter edge-to-edge tricuspid repair for severe tricuspid regurgitation reduces hospitalizations for heart failure. JACC Heart Fail 8:265\u2013276. https:\/\/doi.org\/10.1016\/j.jchf.2019.12.006","journal-title":"JACC Heart Fail"},{"key":"1812_CR11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jcmg.2018.09.028","volume":"12","author":"K Addetia","year":"2019","unstructured":"Addetia K, Harb SC, Hahn RT et al (2019) Cardiac implantable electronic device lead-induced tricuspid regurgitation. JACC Cardiovasc Imaging 12:622\u2013636. https:\/\/doi.org\/10.1016\/j.jcmg.2018.09.028","journal-title":"JACC Cardiovasc Imaging"},{"key":"1812_CR12","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1016\/j.jacc.2017.02.055","volume":"69","author":"JD Chang","year":"2017","unstructured":"Chang JD, Manning WJ, Ebrille E, Zimetbaum PJ (2017) Tricuspid valve dysfunction following pacemaker or cardioverter-defibrillator implantation. J Am Coll Cardiol 69:2331\u20132341. https:\/\/doi.org\/10.1016\/j.jacc.2017.02.055","journal-title":"J Am Coll Cardiol"},{"key":"1812_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.5603\/CJ.a2015.0060","volume":"22","author":"P Arabi","year":"2015","unstructured":"Arabi P, \u00d6zer N, Ate\u015f AH et al (2015) Effects of pacemaker and implantable cardioverter defibrillator electrodes on tricuspid regurgitation and right sided heart functions. Cardiol J 22:637\u2013644. https:\/\/doi.org\/10.5603\/CJ.a2015.0060","journal-title":"Cardiol J"},{"key":"1812_CR14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/pace.12530","volume":"38","author":"R Al-Bawardy","year":"2015","unstructured":"Al-Bawardy R, Krishnaswamy A, Rajeswaran J et al (2015) Tricuspid regurgitation and implantable devices: TR AND IMPLANTABLE DEVICES. Pacing Clin Electrophysiol 38:259\u2013266. https:\/\/doi.org\/10.1111\/pace.12530","journal-title":"Pacing Clin Electrophysiol"},{"key":"1812_CR15","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.amjcard.2015.12.038","volume":"117","author":"FN Delling","year":"2016","unstructured":"Delling FN, Hassan ZK, Piatkowski G et al (2016) Tricuspid regurgitation and mortality in patients with transvenous permanent pacemaker leads. Am J Cardiol 117:988\u2013992. https:\/\/doi.org\/10.1016\/j.amjcard.2015.12.038","journal-title":"Am J Cardiol"},{"key":"1812_CR16","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/heartjnl-2013-304673","volume":"100","author":"U H\u00f6ke","year":"2014","unstructured":"H\u00f6ke U, Auger D, Thijssen J et al (2014) Significant lead-induced tricuspid regurgitation is associated with poor prognosis at long-term follow-up. Heart 100:960\u2013968. https:\/\/doi.org\/10.1136\/heartjnl-2013-304673","journal-title":"Heart"},{"key":"1812_CR17","doi-asserted-by":"publisher","first-page":"e0235230","DOI":"10.1371\/journal.pone.0235230","volume":"15","author":"J Seo","year":"2020","unstructured":"Seo J, Kim D-Y, Cho I et al (2020) Prevalence, predictors, and prognosis of tricuspid regurgitation following permanent pacemaker implantation. PLoS ONE 15:e0235230. https:\/\/doi.org\/10.1371\/journal.pone.0235230","journal-title":"PLoS ONE"},{"key":"1812_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2020.05.062","author":"N Papageorgiou","year":"2020","unstructured":"Papageorgiou N, Falconer D, Wyeth N et al (2020) Effect of tricuspid regurgitation and right ventricular dysfunction on long-term mortality in patients undergoing cardiac devices implantation: > 10-year follow-up study. Int J Cardiol. https:\/\/doi.org\/10.1016\/j.ijcard.2020.05.062","journal-title":"Int J Cardiol"},{"key":"1812_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.amjcard.2020.05.039","volume":"130","author":"Y Seo","year":"2020","unstructured":"Seo Y, Nakajima H, Ishizu T et al (2020) Comparison of outcomes in patients with heart failure with versus without lead-induced tricuspid regurgitation after cardiac implantable electronic devices implantations. Am J Cardiol 130:85\u201393. https:\/\/doi.org\/10.1016\/j.amjcard.2020.05.039","journal-title":"Am J Cardiol"},{"key":"1812_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/europace\/eus342","volume":"15","author":"MN Nazmul","year":"2013","unstructured":"Nazmul MN, Cha Y-M, Lin G et al (2013) Percutaneous pacemaker or implantable cardioverter-defibrillator lead removal in an attempt to improve symptomatic tricuspid regurgitation. EP Eur 15:409\u2013413. https:\/\/doi.org\/10.1093\/europace\/eus342","journal-title":"EP Eur"},{"key":"1812_CR21","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jcin.2019.10.058","volume":"13","author":"M Taramasso","year":"2020","unstructured":"Taramasso M, Gavazzoni M, Pozzoli A et al (2020) Outcomes of TTVI in patients with pacemaker or defibrillator leads. JACC Cardiovasc Interv 13:554\u2013564. https:\/\/doi.org\/10.1016\/j.jcin.2019.10.058","journal-title":"JACC Cardiovasc Interv"},{"key":"1812_CR22","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16:233\u2013271. https:\/\/doi.org\/10.1093\/ehjci\/jev014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1812_CR23","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.echo.2010.05.010","volume":"23","author":"LG Rudski","year":"2010","unstructured":"Rudski LG, Lai WW, Afilalo J et al (2010) Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography. J Am Soc Echocardiogr 23:685\u2013713. https:\/\/doi.org\/10.1016\/j.echo.2010.05.010","journal-title":"J Am Soc Echocardiogr"},{"key":"1812_CR24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/ehjci\/jet105","volume":"14","author":"P Lancellotti","year":"2013","unstructured":"Lancellotti P, Tribouilloy C, Hagendorff A et al (2013) Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 14:611\u2013644. https:\/\/doi.org\/10.1093\/ehjci\/jet105","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1812_CR25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00508-018-1330-3","volume":"130","author":"M Schneider","year":"2018","unstructured":"Schneider M, Binder T (2018) Echocardiographic evaluation of the right heart. Wien Klin Wochenschr 130:413\u2013420. https:\/\/doi.org\/10.1007\/s00508-018-1330-3","journal-title":"Wien Klin Wochenschr"},{"key":"1812_CR26","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.echo.2007.05.022","volume":"21","author":"JB Kim","year":"2008","unstructured":"Kim JB, Spevack DM, Tunick PA et al (2008) The effect of transvenous pacemaker and implantable cardioverter defibrillator lead placement on tricuspid valve function: an observational study. J Am Soc Echocardiogr 21:284\u2013287. https:\/\/doi.org\/10.1016\/j.echo.2007.05.022","journal-title":"J Am Soc Echocardiogr"},{"key":"1812_CR27","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1111\/j.1540-8159.2008.02269.x","volume":"32","author":"M Klutstein","year":"2009","unstructured":"Klutstein M, Balkin J, Butnaru A et al (2009) Tricuspid incompetence following permanent pacemaker implantation. Pacing Clin Electrophysiol 32:S135\u2013S137. https:\/\/doi.org\/10.1111\/j.1540-8159.2008.02269.x","journal-title":"Pacing Clin Electrophysiol"},{"key":"1812_CR28","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/ejhf.1142","volume":"20","author":"K Dickstein","year":"2018","unstructured":"Dickstein K, Normand C, Auricchio A et al (2018) CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients-who is doing what to whom and how? CRT Survey II. Eur J Heart Fail 20:1039\u20131051. https:\/\/doi.org\/10.1002\/ejhf.1142","journal-title":"Eur J Heart Fail"},{"key":"1812_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/pace.13543","volume":"42","author":"MS Cho","year":"2019","unstructured":"Cho MS, Kim J, Lee J-B et al (2019) Incidence and predictors of moderate to severe tricuspid regurgitation after dual-chamber pacemaker implantation. Pacing Clin Electrophysiol 42:85\u201392. https:\/\/doi.org\/10.1111\/pace.13543","journal-title":"Pacing Clin Electrophysiol"},{"key":"1812_CR30","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1540-8175.2011.01565.x","volume":"29","author":"MQ Najib","year":"2012","unstructured":"Najib MQ, Vinales KL, Vittala SS et al (2012) Predictors for the development of severe tricuspid regurgitation with anatomically normal valve in patients with atrial fibrillation: severe functional TR in AF. Echocardiography 29:140\u2013146. https:\/\/doi.org\/10.1111\/j.1540-8175.2011.01565.x","journal-title":"Echocardiography"},{"key":"1812_CR31","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/pace.12701","volume":"38","author":"RC Lee","year":"2015","unstructured":"Lee RC, Friedman SE, Kono AT et al (2015) Tricuspid regurgitation following implantation of endocardial leads: incidence and predictors: tricuspid regurgitation following endocardial leads. Pacing Clin Electrophysiol 38:1267\u20131274. https:\/\/doi.org\/10.1111\/pace.12701","journal-title":"Pacing Clin Electrophysiol"},{"key":"1812_CR32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.118.007124","author":"NEG Beurskens","year":"2019","unstructured":"Beurskens NEG, Tjong FVY, de Bruin-Bon RHA et al (2019) Impact of leadless pacemaker therapy on cardiac and atrioventricular valve function through 12 months of follow-up. Circ Arrhythm Electrophysiol. https:\/\/doi.org\/10.1161\/CIRCEP.118.007124","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1812_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13019-015-0244-7","author":"M Andreas","year":"2015","unstructured":"Andreas M, Gremmel F, Habertheuer A et al (2015) Case report: pacemaker lead perforation of a papillary muscle inducing severe tricuspid regurgitation. J Cardiothorac Surg. https:\/\/doi.org\/10.1186\/s13019-015-0244-7","journal-title":"J Cardiothorac Surg"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01812-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-021-01812-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01812-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T05:46:58Z","timestamp":1622785618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-021-01812-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1812"],"URL":"https:\/\/doi.org\/10.1007\/s00392-021-01812-3","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,10]]},"assertion":[{"value":"12 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Martin Andreas has served as a Proctor for Edwards and Abbott, served as an Advisor for Medtronic and reported receiving Institutional Grants from LSI, Abbott, Edwards, and Medtronic during the conduct of the study. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}